Pfizer Inc.

What's your position on ?
Why are you ish?
You voted ish on Vote again
Posts appear on the My Feed page of subscribers to this ticker
Last vote:
  • Dec. 4, 2012, 8:13 AM

    An appeals court ruling yesterday that dismissed the conviction of a sales rep who sold a drug for non-FDA approved uses could have major ramifications for pharmaceutical companies, which have paid billions in fines for doing just that. Two out of three judges agreed with Alfred Caronia that his rights to free speech were violated. The government is expected to appeal the case, which could find its way to the Supreme Court.

    | Dec. 4, 2012, 8:13 AM | 9 Comments
  • Dec. 3, 2012, 2:01 PM

    Pfizer (PFE +0.2%) says it's laying off some of the U.S. sales reps who promote its drugs to doctors. The drug giant saw an 18% Y/Y drop in U.S. revenue in Q3, thanks in large part to an 87% decline in Lipitor sales following the arrival of generic competition.

    | Dec. 3, 2012, 2:01 PM
  • Nov. 30, 2012, 2:46 PM
    Indian generic drugmaker Ranbaxy Laboratories (RBXLY.PK) says it will stop manufacturing atorvastatin, its version of Pfizer's (PFE +0.4%) cholesterol drug Lipitor, while it gets to the bottom of the cause of a recent recall. Earlier this month, the drug developer recalled certain lots of the drug after discovering contamination with tiny glass particles.
    | Nov. 30, 2012, 2:46 PM | 3 Comments
  • Nov. 28, 2012, 11:57 AM

    Pfizer (PFE +0.9%) looks to be fairly valued, says MKM Partners. The firm cut the shares to Neutral today, saying that it expects the drug giant to only launch three new products between 2013 and 2017, which is the lowest number and least relative revenue contribution of all its U.S. peers. The limited pipeline means significantly reduced news flow over the next few years, which also means fewer upside catalysts.

    | Nov. 28, 2012, 11:57 AM | 2 Comments
  • Nov. 28, 2012, 8:34 AM

    Pfizer (PFE) completes the acquisition of NextWave Pharmaceuticals in deal worth an initial $255M plus milestone amounts of up to $425M. With the purchase, Pfizer gains access to Quillivant XR, an FDA-approved treatment for attention deficit hyperactivity disorder (ADHD). (PR)

    | Nov. 28, 2012, 8:34 AM
  • Nov. 27, 2012, 10:51 AM

    Aceto Pharmaceutical (ACET +2.1%) gets a boost today from what appears to be a delayed reaction to yesterday's launch of its generic Clindamycin Palmitate Hydrochloride for Oral Solution, an FDA approved generic version of Pfizer's (PFE -0.6%) Cleocin Pediatric. U.S. market sales for Clindamycin Palmitate Hydrochloride - which is an antibiotic that is used to treat serious bacterial infections - were approximately $59M for the twelve months ended June 30.

    | Nov. 27, 2012, 10:51 AM
  • Nov. 27, 2012, 10:36 AM

    IntelliPharmaCeutics (IPCI -4.3%) slips despite reporting successful results of its initial Phase I clinical trial of a controlled-release form of pregabalin, for the treatment of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, spinal cord injury and fibromyalgia. The results of the trial showed the drug was comparable to Pfizer's (PFE -0.6%) Lyrica, and the IPCI now plans to initiate additional Phase I trials in 2013.

    | Nov. 27, 2012, 10:36 AM
  • Nov. 21, 2012, 10:40 AM

    Weight loss drug makers get a lift today after Aetna (AET -0.6%) revises its criteria under which the insurer considers weight reduction medications as "medically necessary" for treatment of obesity. In a Clinical Policy Bulletin revision dated yesterday, AET identified certain medications that have been approved by the FDA for weight reduction which would be covered under its policy: Qsymia, marketed by VIVUS (VVUS +13.2%), Belviq from Arena Pharmaceuticals (ARNA +2.9%), Didrex from Pfizer (PFE +0.1%), Xenical from Roche (RHHBY +0.3) and GlaxoSmithKline's (GSK +0.2%) Alli. Orexigen (OREX +6.5%), although not named in the bulletin, is also higher on the news.

    | Nov. 21, 2012, 10:40 AM | 11 Comments
  • Nov. 21, 2012, 8:37 AM
    Mexican regulators reject Nestle's (NSRGY.PK) takeover of Pfizer's (PFE) baby foods business in the country, calculating it would give it a 71%-88% share of the market. Nestle, whose fifth largest market by sales is Mexico, says it will still try to resolve the regulators' concerns. Some sources say Danone (DANOY.PK) could be a potential bidder now for PFE’s Mexican assets.
    | Nov. 21, 2012, 8:37 AM
  • Nov. 19, 2012, 9:31 AM

    Pfizer's (PFE) Lyrica once-daily drug met its main goal in patients with fibromyalgia, a pain condition that affects 5M Americans, in Phase III trials, enabling them to enjoy a longer period without pain than a placebo. The study is the second of three late-stage trials testing a controlled-release version of Lyrica; in the first set of testing, the medicine failed in patients with certain types of seizures. (PR)

    | Nov. 19, 2012, 9:31 AM | 1 Comment
  • Nov. 12, 2012, 5:28 PM

    Pfizer (PFE) has agreed to pay $67.5M to settle a class-action lawsuit filed by former Wyeth shareholders who claimed they were misled about risks associated with the antidepressant Pristiq. The all-cash settlement comes just one month after it agreed to pay $164M to settle separate charges accusing it of misleading investors about clinical trial results for its arthritis drug Celebrex.

    | Nov. 12, 2012, 5:28 PM | 1 Comment
  • Nov. 12, 2012, 5:04 PM

    Watson Pharmaceuticals (WPI +0.2%) gave back most of the days gains made earlier today following its announcement that it received approval from the FDA on its Abbreviated New Drug Application for Sildenafil Tablets, the generic equivalent to Pfizer's (PFE) Revatio. WPI plans to begin shipping the product as quickly as possible.

    | Nov. 12, 2012, 5:04 PM
  • Nov. 8, 2012, 10:24 AM

    Pfizer's (PFE -0.2%) Viagra patent has been ruled no longer valid by Canada's top court, backing an appeal by generic drug maker Teva Pharmaceutical (TEVA +0.1%) that claimed PFE hadn't provided sufficient details when it initially filed its patent registration.

    | Nov. 8, 2012, 10:24 AM | 1 Comment
  • Nov. 7, 2012, 12:42 PM

    Auxilium Pharmaceuticals (AUXL -8%) drops after terminating its collaboration agreement with Pfizer (PFE -1%) to develop the drug Xiapex, a treatment for Dupuytren's disease, in the European Union and certain other European and Eurasian countries. The agreement will terminate no later than April 24, 2013, after which rights to commercialize Xiapex will revert to AUXL.

    | Nov. 7, 2012, 12:42 PM
  • Nov. 6, 2012, 5:18 PM

    Pfizer (PFE) says the FDA has approved Xeljanz for the treatment of adults with moderately to severely active rheumatoid arthritis, who have had an inadequate response or intolerance to methotrexate. The drug may be used as a single therapy treatment, or in combination with methotrexate or other non-biologic disease-modifying antirheumatic drugs. Shares +1.2% AH.

    | Nov. 6, 2012, 5:18 PM
  • Nov. 6, 2012, 9:36 AM

    Taking multivitamins every day didn't reduce the risk of a heart attack or stroke in an 11-year study of over 14,500 men over the age of 50, although there did seem to be a reduced risk of cancer. Companies that operate in the sector include Pfizer (PFE), which supplied the vitamins for the study, NBTY (NTY) and Schiff (SHF).

    | Nov. 6, 2012, 9:36 AM | 2 Comments
Company Description
Pfizer Inc is a research-based biopharmaceutical company. The Company has five operating segments: Primary Care; Specialty Care and Oncology; Established Products and Emerging Markets; Animal Health; and Consumer Healthcare.